Literature DB >> 6182970

Preoperative chemotherapy for giant cell carcinoma of the thyroid.

G A Spanos, D WolK, M R Desner, A Khan, N Platt, R A Khafif, E P Cortes.   

Abstract

Reported is the case of a 24-year-old white man with inoperable giant cell carcinoma of the thyroid who achieved tumor regression following therapy with bleomycin, Adriamycin and cisplatinum. After 2 courses of chemotherapy, the tumor was deemed operable, and the patient underwent total thyroidectomy followed by radiation to the neck and upper mediastinum without maintenance chemotherapy. Two-and-one-half years after the initial diagnosis, he developed pulmonary metastases which again responded to Adriamycin and cisplatinum therapy. The above approach suggests that inoperable thyroid carcinoma can be made operable by preoperative combination chemotherapy. This treatment program deserves further exploration for a greater number of patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6182970     DOI: 10.1002/1097-0142(19821201)50:11<2252::aid-cncr2820501103>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer.

Authors:  P De Besi; B Busnardo; S Toso; M E Girelli; D Nacamulli; N Simioni; D Casara; P Zorat; M V Fiorentino
Journal:  J Endocrinol Invest       Date:  1991-06       Impact factor: 4.256

2.  A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients.

Authors:  B Busnardo; O Daniele; M R Pelizzo; R Mazzarotto; D Nacamulli; D Devido; C Mian; M E Girelli
Journal:  J Endocrinol Invest       Date:  2000-12       Impact factor: 4.256

3.  A Case Report on Multiple Stones in the Thyroid Gland in Association with Sclerosing Thyroiditis: An Unusual Encounter.

Authors:  Gaurav Shandilya; Ravish Kumar Sinha; Nishith Ekka; Vinod Kumar
Journal:  J Clin Diagn Res       Date:  2017-02-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.